The 3rd World Congress on Rare Skin Diseases: 01-03 July 2026
The 3rd World Congress on Rare Skin Diseases — a place to deepen knowledge, discover the latest research, and connect with people who truly care about improving life for EB patients.
The 3rd World Congress on Rare Skin Diseases 2026
01-03 July 2026
Versailles, France
BIO International Convention: 22-25 June 2026
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from around the world.
BIO International Convention
22-25 June 2026
San Diego, US
https://convention.bio.org/about-bio
EADV Symposium 2026: 07-09 May 2026
The annual EADV Symposium stands as a premier international gathering devoted to dermatology and venereology, offering a dynamic platform for exchanging knowledge, collaboration, and presenting cutting-edge research findings.
EADV Symposium 2026
07-09 May 2026
Athens, Greece
https://eadv.org/symposium/
Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.
The granted patent is broad in scope and covers both the formulation currently being used in the international clinical study STEP as well as future generations of products containing TCP-25.
TCP-25 is already protected by patents in Europe and the United States and has also been granted Orphan Drug Designation in the United States.
“A strong intellectual property position is essential for us, and this new patent provides broad protection in a strategically important market,” says Helene Hartman, CEO of Xinnate AB.
Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.
Det godkända patentet är brett och omfattar både den formulering som nu ingår i den internationella kliniska studien STEP och kommande generationer av produkter innehållande TCP-25.
TCP-25 är sedan tidigare skyddad av patent i både Europa och USA och har även särläkemedelsstatus i USA.
Ett starkt immateriellt skydd är viktigt och det nya patentet ger oss ett brett skydd i en för oss strategiskt viktig marknad säger Helene Hartman, VD för Xinnate AB.
